EAACI Congress 2024

31 May - 03 June 2024 Valencia, Spain

FT 17 - Flash talks on Angioedema

Sunday 02 Jun, 13:15 PM - 14:45 PM Valencia, Spain
Palma Flash Talks
Abstract Text
13:15 000210
The Determinants of Acute Attack Development in Hereditary Angioedema Patients Undergoing Dental Interventions
Abstract Text
13:22 000277
Real-world Effectiveness of Lanadelumab in Patients with HAE Type I/II: Data across the Four Countries from the INTEGRATED Study
Abstract Text
13:29 000984
A Physician-based Brazilian Registry for Hereditary Angioedema: insights from the first 508 Patients
Abstract Text
13:36 001256
Preimplantation genetic testing in hereditary angioedema: prevention outperforms treatment
Abstract Text
13:43 000011
Hereditary Angioedema Attack Diary Determination of the Effect of Mobile Application on Patients' Quality of Life and Treatment Compliance Level
Abstract Text
13:50 000498
Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design
Abstract Text
13:57 000711
Attack-free Rates and Attack Characteristics in Patients with Hereditary Angioedema Receiving Non-androgen Long-term Prophylaxis
Abstract Text
14:04 000721
Use of Patient-Reported Outcome Measurements Among Angioedema-Treating Physicians
Abstract Text
14:11 001201
Evaluation of Anxiety, Depression, and Death Anxieties in Patients Diagnosed with Hereditary Angioedema
Abstract Text
14:18 001298
Pharmacodynamic Effects of Deucrictibant on Carrageenan-induced Edema in Humanized Bradykinin B2 Receptor Transgenic Sprague Dawley Rat
Abstract Text
14:25 001355
Development of Kallikrein-Kinin System Biomarker Assays to Investigate Bradykinin-mediated Diseases
Abstract Text
14:32 000478
Exploring the Relationship Between Airway Attacks and Patient-Reported Outcomes in Hereditary Angioedema